Tags : Targets


Takeda Collaborates with Evotec on RNA Targeting Drug Development

Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class […]Read More


Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer

Shots: Artios to receive $30M up front & near-term milestones, ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally, Artios has opt-in rights for joint development & commercialization of the programs Merck has the right to opt into exclusive development & commercialization of compounds on up to 8 targets […]Read More


Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration

Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies Egle has leveraged its unique bioinformatic & translational capabilities to identify targets Following the achievement of the target identification, Egle will receive an R&D […]Read More